Journal of Bone and Joint Infection (Apr 2021)

Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous

  • I. Kouki,
  • C. Montagner,
  • W. Mauhin,
  • J. London,
  • T. Lazard,
  • S. Grimbert,
  • V. Zeller,
  • O. Lidove

DOI
https://doi.org/10.5194/jbji-6-131-2021
Journal volume & issue
Vol. 6
pp. 131 – 134

Abstract

Read online

We describe a 79-year-old man with spondylodiscitis and unknown pathogen, treated with cefazolin and rifampicin. He developed a massive digestive hemorrhage. Prothrombin time was prolonged with severe vitamin-K-dependent clotting-factor deficiency. Severe bleeding can occur during cefazolin and rifampicin use. This deficiency should be assessed before prescribing cefazolin–rifampicin and prothrombin time monitored.